Organisation paid for research Program year 2023 Source: CMS Open Payments

Broome Oncology LLC

Neither a doctor nor a teaching hospital

Research payments

$178,364

34 payments

Through program year 2023, Broome Oncology LLC is reported as receiving $178,364 in research payments, across 34 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $16,940 6
2022 Research $6,810 4
2021 Research $17,215 6
2020 Research $32,559 8
2019 Research $104,840 10

Breakdown

Who paid Research payments · program years 2019–2023
  1. Eli Lilly and Company $103,230 11 payments
  2. Novartis Pharmaceuticals Corporation $23,400 2 payments
  3. Helsinn Healthcare SA $22,527 5 payments
  4. Celgene Corporation $18,750 3 payments
  5. Janssen Research & Development, LLC $4,248 3 payments
  6. Amgen Inc. $3,624 6 payments
  7. Mirati Therapeutics, Inc. $1,912 2 payments
  8. E.R. Squibb & Sons, L.L.C. $673 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $85,057 5 payments
  2. An Open Label Multi Center Rollover Protocol for Patients Who Have Participated in A Novartis Sponsored Ribociclib Lee011 Study and Are Continuing to Benefit From Ribociclib As Single Agent Or in Combination With Other Investigational Treatments $23,400 2 payments
  3. Celgene - Connect MM $16,125 1 payment
  4. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer NSCLC $13,457 2 payments
  5. Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 VS Investigator's Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy $11,045 4 payments
  6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) $7,900 2 payments
  7. A Randomized Open-Label Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk Node Positive Early Stage Hormone Receptor Positive Human Epidermal Receptor 2 Negative Breast Cancer $6,066 1 payment
  8. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma $4,248 3 payments
  9. LCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 2 $2,424 4 payments
  10. Connect MM- The Multiple Myeloma Disease Registry (OS002982) $2,250 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record